BullFrog AI Holdings, Inc. is a biotechnology company that applies artificial intelligence and machine learning to improve the drug development process. The company’s core asset is the bfLEAP™ platform an AI powered analytical tool derived from technology created at the Johns Hopkins University Applied Physics Lab. Through bfLEAP™ the company offers data analysis services that help identify drug targets predict patient response and streamline clinical trial design. BullFrog AI Holdings also pursues a drug asset enhancement strategy whereby it acquires rights to promising compounds uses its platform to define optimal patient profiles conducts validation studies and then seeks to outlicense or sell the rescued assets. The firm operates primarily in the life sciences sector serving biopharmaceutical companies academic institutions and research organizations.

Revenue is generated principally through three activities. First the company provides fee for service contract analysis where clients pay for bfLEAP™ powered data sets evaluation and insight delivery. Second it enters collaborative arrangements with biopharmaceutical partners that combine fee for service payments with milestone based success fees tied to predefined development goals. Third it acquires rights to drug candidates applies its platform to de risk the assets and then sells or outlicenses the improved compounds earning upfront payments milestone payments and royalties on future sales. While the firm has licensed several therapeutic candidates such as a siRNA targeting Beta2 spectrin and an improved mebendazole formulation these programs remain in preclinical or early clinical stages and have not yet produced significant sales.

BullFrog AI Holdings occupies a niche at the intersection of artificial intelligence and drug development where it differentiates itself through a proprietary platform that can analyze high dimensional and heterogeneous data sets without requiring extensive custom code. The bfLEAP™ tool is designed to work with both large volume data and short and wide formats enabling it to uncover patterns that many open source alternatives may miss. Competitors in the AI driven healthcare space include large technology firms offering cloud based analytics specialized bioinformatics companies and internal data science teams at major pharmaceutical corporations. Despite facing opponents with greater financial resources the company claims advantages from its exclusive licenses with Johns Hopkins University Applied Physics Lab George Washington University and other research institutions which give it access to protected algorithms and proprietary libraries. Its emphasis on applying AI to rescue failed drug assets and to design precision medicine trials further sets it apart from pure software vendors that do not engage in therapeutic development.

The company’s customers include biopharmaceutical firms academic medical centers research foundations and non profit organizations engaged in drug discovery and development. Specific partners named in the filing are the FSHD Society a leading non profit organization focused on rare neuromuscular disorders Eleison Pharmaceuticals Inc. a Phase III oncology company the Lieber Institute for Brain Development Johns Hopkins University and George Washington University. Additionally BullFrog AI Holdings has worked with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences and has engaged an unnamed international collaborator in the cardiovascular device field to analyze clinical trial data. These relationships provide the firm with access to diverse data sets and opportunities to validate its AI driven insights in real world settings.